Cargando…

Mitochondrial DNA in Uremia and New Targets to Treat Myocardial Hypertrophy in the Cardiorenal Syndrome

[Figure: see text]

Detalles Bibliográficos
Autor principal:	Bayliss, George
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Original Research - Preclinical
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436808/ https://www.ncbi.nlm.nih.gov/pubmed/36061339 http://dx.doi.org/10.1016/j.jacbts.2022.06.005

Ejemplares similares

Cardiac Spinal Afferent Denervation Attenuates Renal Dysfunction in Rats With Cardiorenal Syndrome Type 2
por: Xia, Zhiqiu, et al.
Publicado: (2022)

Neuregulin-1: A Tonic for Cardiorenal Syndrome? And All Else That Ails Us?
por: Geissler, Andrew K., et al.
Publicado: (2023)

SGLT2 Inhibitor–Induced Sympathoinhibition: A Novel Mechanism for Cardiorenal Protection
por: Herat, Lakshini Y., et al.
Publicado: (2020)

Targeting Myocardial Mitochondria-STING-Polyamine Axis Prevents Cardiac Hypertrophy in Chronic Kidney Disease
por: Han, Wenhao, et al.
Publicado: (2022)

Cardiorenal Tissues Express SARS-CoV-2 Entry Genes and Basigin (BSG/CD147) Increases With Age in Endothelial Cells
por: Ahmetaj-Shala, Blerina, et al.
Publicado: (2020)

Myocardial bioenergetic abnormalities in experimental uremia
por: Chesser, Alistair MS, et al.
Publicado: (2016)

Cardiac Nuclear High-Mobility Group Box 1 Ameliorates Pathological Cardiac Hypertrophy by Inhibiting DNA Damage Response
por: Takahashi, Tetsuya, et al.
Publicado: (2019)

The Diabetic Cardiorenal Nexus
por: D’Elia, John A., et al.
Publicado: (2022)

Uremia
por: Low, J. H.
Publicado: (1883)

Efficacy of a Novel Mitochondrial-Derived Peptide in a Porcine Model of Myocardial Ischemia/Reperfusion Injury
por: Sharp, Thomas E., et al.
Publicado: (2020)

Cardiac Expression of Factor X Mediates Cardiac Hypertrophy and Fibrosis in Pressure Overload
por: Guo, Xinji, et al.
Publicado: (2020)

Macrophage-Derived Exosomal Mir-155 Regulating Cardiomyocyte Pyroptosis and Hypertrophy in Uremic Cardiomyopathy
por: Wang, Bin, et al.
Publicado: (2020)

Carpal tunnel syndrome in uremia
por: Shubhakaran, K. P.
Publicado: (2015)

Novel Junctophilin-2 Mutation A405S Is Associated With Basal Septal Hypertrophy and Diastolic Dysfunction
por: Quick, Ann P., et al.
Publicado: (2017)

Apoptosis signal-regulating kinase 1 inhibition attenuates cardiac hypertrophy and cardiorenal fibrosis induced by uremic toxins: Implications for cardiorenal syndrome
por: Savira, Feby, et al.
Publicado: (2017)

Targeting IL-6 Trans-Signaling: Amplifying the Benefits of IL-6 Inhibition in Myocardial Infarction
por: Aukrust, Pål, et al.
Publicado: (2021)

Role of TLR4/MyD88 Signaling Pathway in the Occurrence and Development of Uremia-Induced Myocardial Hypertrophy and Possible Mechanism
por: Zhu, Huiping, et al.
Publicado: (2021)

Low-Density Lipoprotein Receptor–Related Protein-1 Is a Therapeutic Target in Acute Myocardial Infarction
por: Toldo, Stefano, et al.
Publicado: (2017)

A Cardiac Amino-Terminal GRK2 Peptide Inhibits Maladaptive Adipocyte Hypertrophy and Insulin Resistance During Diet-Induced Obesity
por: Manaserh, Iyad H., et al.
Publicado: (2022)

Mitochondrial Dysfunction: An Emerging Link in the Pathophysiology of Cardiorenal Syndrome
por: Shi, Shuqing, et al.
Publicado: (2022)

The Cardiorenal Syndrome
por: Rosner, Mitchell H., et al.
Publicado: (2011)

Cardiorenal syndrome
por: Schetz, Miet
Publicado: (2009)

Cardiorenal syndrome
por: Ye, Wen Qing Wendy, et al.
Publicado: (2023)

Monocytes in Uremia
por: Girndt, Matthias, et al.
Publicado: (2020)

Experimental Uremia
Publicado: (1882)

Retracted: Role of TLR4/MyD88 Signaling Pathway in the Occurrence and Development of Uremia-Induced Myocardial Hypertrophy and Possible Mechanism
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

Editorial: New Advances in Cardiorenal Syndrome
por: Calvier, Laurent, et al.
Publicado: (2022)

Cardiorenal Systems Modeling: Left Ventricular Hypertrophy and Differential Effects of Antihypertensive Therapies on Hypertrophy Regression
por: Hallow, K. Melissa, et al.
Publicado: (2021)

Injectable Myocardial Matrix Hydrogel Mitigates Negative Left Ventricular Remodeling in a Chronic Myocardial Infarction Model
por: Diaz, Miranda D., et al.
Publicado: (2021)

Klotho downregulation contributes to myocardial damage of cardiorenal syndrome in sepsis
por: Yan, Fei, et al.
Publicado: (2020)

Macrophages of the Cardiorenal Axis and Myocardial Infarction
por: Kercheva, Maria, et al.
Publicado: (2023)

Extracellular Matrix Biomaterial Therapy for Myocardial Infarction: New Delivery Route and Immunomodulatory Effects
por: Christman, Karen L.
Publicado: (2023)

Is it Time for Trials on Preventing Immune-Mediated Myocardial Damage?
por: Peyster, Eliot G., et al.
Publicado: (2021)

Diffusion Tensor Cardiac Magnetic Resonance Reveals Exosomes From Cardiosphere-Derived Cells Preserve Myocardial Fiber Architecture After Myocardial Infarction
por: Nguyen, Christopher T., et al.
Publicado: (2018)

Selective Interleukin-6 Trans-Signaling Blockade Is More Effective Than Panantagonism in Reperfused Myocardial Infarction
por: George, Marc Jonathan, et al.
Publicado: (2021)

New aspects in cardiorenal syndrome and HFpEF
por: Méndez, Ana Belén, et al.
Publicado: (2022)

Cardiorenal Syndrome: New Pathways and Novel Biomarkers
por: Gembillo, Guido, et al.
Publicado: (2021)

Cardiorenal Syndromes and Sepsis
por: Chelazzi, C., et al.
Publicado: (2011)

Biomarkers in Cardiorenal Syndromes
por: Fu, Shihui, et al.
Publicado: (2018)

Biomarkers in Cardiorenal Syndrome
por: Goffredo, Giovanni, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lbancbu1cl8g48iql2sfv5bjcu